To determine whether macropinocytosis is involved in RGNNV entry into hMMES1 cells, we used a panel of compounds to treat the cells prior to viral infection, including EIPA (macropinocytosis inhibitor), Rottlerin (macropinocytosis inhibitor), CPZ (CME inhibitor), and Nystatin (caveolin inhibitor). The gene discussed is CPZ; the disease is viral infectious disease.